Article in Bioconjugate chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Jiang HeDepartment of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia 22908, United States.ORCID 0000-0001-7600-4604
Jinjin FengDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Yang SuDepartment of Anesthesia, University of California, San Francisco, California 94143, United States.
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Bin LiuDepartment of Anesthesia, University of California, San Francisco, California 94143, United States.
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancerR01CA223767 · NCI · UNIVERSITY OF VIRGINIA · PI HE, JIANG, LIU, BIN · 2018 to 2022
$2.8M
Mapping a clinically significant internalizing tumor epitope space.R01CA118919 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, BIN · 2006 to 2013
$2.5M
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma TherapyR01CA154561 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEO, YOUNGHO · 2011 to 2016
$1.9M
Identifying antigens bound by novel scFvs targeting all subtypes of mesotheliomaR01CA129491 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, BIN · 2010 to 2013
$1.2M
Targeted liposomal radiotherapy of malignant mesotheliomaR01CA135358 · NCI · UNIVERSITY OF VIRGINIA · PI HE, JIANG · 2008 to 2011
Single chain antibody fragment (scFv) is a promising agent for imaging and targeted therapy. The objective of the study is to evaluate a kit formulation for
Indexed as
AnimalsIsotope LabelingMesothelioma, MalignantMiceOrganotechnetium CompoundsReproducibility of ResultsSingle-Chain AntibodiesTissue DistributionXenograft Model Antitumor AssaysOrganotechnetium CompoundsSingle-Chain Antibodies
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.